The Billion-Dollar Race to Slow Ageing
Billions of dollars are pouring into the idea that ageing is a disease we can treat. The longevity biotech sector attracted $8.49 billion in private investment across 325 deals in 2024, according to Longevity.Technology’s Annual Longevity Investment Report. Major pharmaceutical companies spent over $65 billion acquiring biotech firms through October 2025, surpassing full-year totals for 2024, 2022, and 2021 combined. Headlines have followed accordingly, heralding a new era in which ageing itself becomes a treatable condition. Yet behind the capital flows, an important question persists: how much of what is being promised is grounded in robust human evidence, and how much remains preclinical aspiration dressed in press-release language?
The answer, as with most frontier science, sits somewhere in between.
Understanding What the Field Is Actually Trying to Do
The longevity biotech sector is not, at its core, about living forever. The more precise and scientifically defensible goal is extending healthspan, the period of life spent in good biological health, rather than simply adding years to a lifespan that may already be characterised by chronic disease. According to the United Nations World Population Prospects 2024, the number of individuals aged 65 or older is expected to double from 761 million in 2021 to 1.6 billion within the next two to three decades. That demographic reality has given the science urgency and the market a credible foundation.
Longevity interventions broadly target what researchers call the hallmarks of ageing: cellular senescence, epigenetic alterations, mitochondrial dysfunction, chronic inflammation, and dysregulated nutrient-sensing pathways. Rather than treating individual diseases as they emerge, geroscience aims to intervene at the biological level before age-related decline begins. The appeal is considerable. The challenge is translating that appeal into therapies that demonstrably work in people.
Where the Science Is Most Credible
Among the most discussed classes of compounds in longevity research are GLP-1 receptor agonists, drugs already approved for obesity and type 2 diabetes. A paper published in Nature Biotechnology in November 2025 argued that the broad systemic benefits of GLP-1 drugs position them as the closest thing currently available to a genuine gerotherapeutic, capable of improving multiple organ systems, reducing mortality risk, and targeting several hallmarks of ageing simultaneously. No drug has yet been formally approved as a longevity therapeutic by the US Food and Drug Administration, but GLP-1s are widely regarded as the most plausible near-term candidate.
SGLT2 inhibitors, another class of metabolic drugs, have attracted similar interest. Experimental models have linked them to reduced markers of cellular senescence, improved mitochondrial health, and activation of longevity-associated pathways including AMPK and SIRT1. One clinical study found that the SGLT2 inhibitor henagliflozin lengthened telomeres in 90.5% of participants after 26 weeks, compared with 65.6% in the placebo group. Whether these molecular signals translate to meaningful clinical outcomes in ageing populations remains to be demonstrated at scale.
Senolytics, drugs designed to selectively clear senescent or so-called zombie cells that accumulate with age and drive chronic inflammation, have shown promise in both animal models and limited human studies. The combination of dasatinib and quercetin improved physical function in patients with idiopathic pulmonary fibrosis in early trials. However, the field received a sobering reminder in September 2025 when Unity Biotechnology, once one of the most prominent senolytic companies, shuttered after failing to meet the primary endpoint in its trial for diabetic macular edema. The closure underlined that mechanistic elegance in the laboratory does not guarantee efficacy in the clinic.
Epigenetic Reprogramming: Ambitious Science, Early Days
Perhaps the most ambitious thread in longevity biotech is partial epigenetic reprogramming. The principle involves using variants of Yamanaka transcription factors, the same molecular tools used to create induced pluripotent stem cells, to reset the epigenetic age of cells without reverting them to a fully undifferentiated state. In animal models, the approach has restored retinal function, improved liver biology, and extended lifespan. In 2025, Life Biosciences announced FDA clearance for its Investigational New Drug application for ER-100, a gene therapy delivering three Yamanaka factors via intravitreal injection for optic neuropathies, with first-in-human trials planned for early 2026.
NewLimit, backed by Coinbase co-founder Brian Armstrong with $280 million in cumulative funding, reported by December 2025 that it was close to having clinic-ready reprogramming therapies for liver and immune system rejuvenation. Altos Labs, the $3 billion cellular rejuvenation company backed in part by Amazon founder Jeff Bezos, appointed Dr Joan Mannick as Chief Medical Officer in mid-2025, a move widely interpreted as preparation for the transition into human trials. Retro Biosciences, funded by OpenAI chief executive Sam Altman, announced in August 2025 that an AI collaboration with OpenAI had made reprogramming 50 times more efficient. The company has also initiated its first human trial of RTR242, a small molecule targeting lysosomal function and autophagy in Alzheimer’s disease.
The involvement of AI in drug discovery has been a recurring theme. Insilico Medicine’s AI-driven pipeline identified a novel inhibitor of the kinase TNIK and advanced it through a successful Phase 2a clinical trial in idiopathic pulmonary fibrosis, a result described by multiple experts as among the most significant breakthroughs of 2025 for longevity-focused biotech.
The Biomarker Problem
A persistent structural challenge for the entire field is the absence of universally accepted biomarkers of biological ageing. Without agreed-upon ways to measure whether an intervention is actually slowing or reversing ageing at the cellular level, clinical trials struggle to demonstrate efficacy on meaningful timescales. Cardiovascular medicine resolved this problem decades ago with measures such as LDL cholesterol; geroscience has not yet found its equivalent.
Epigenetic clocks, including newer-generation tools such as GrimAge and DunedinPACE, have emerged as candidate biomarkers. These algorithms use DNA methylation patterns to estimate biological age and have shown predictive power for mortality, cardiovascular disease, and cognitive decline in large longitudinal studies. However, as a paper published in npj Aging in December 2025 noted, wide adoption of standardised biomarker collection in clinical trials will be essential if longevity biotechnology companies are to produce data that can be meaningfully compared and validated across the field.
Therapeutic plasma exchange, a technique involving the partial removal and replacement of blood plasma, generated interest in 2025 when the first published human trial data emerged from a study conducted by Circulate Health in collaboration with the Buck Institute for Research on Aging. The data showed reductions in participants’ biological age as measured by multi-omic profiling. Aging researcher Dr Matt Kaeberlein, a member of Circulate Health’s scientific advisory board, commenting on the findings, noted that the results showed “evidence for improvements in a variety of these multi-omic biological age estimates, all consistent with the idea that therapeutic plasma exchange is moving biomarkers of health in the right direction.” He added that he was “pretty bullish” on the likelihood that some form of the therapy would yield genuine health benefits, though he acknowledged the early-stage nature of the evidence.
The Access Problem
A paper published in Biogerontology in July 2025 highlighted the stark inequity emerging within the longevity sector, noting that programmes offered by high-end clinics typically cost tens of thousands of US dollars annually, covering diagnostics such as whole genome sequencing, epigenetic clocks, and VO2 max testing. The authors cautioned that this pricing structure creates a clear stratification in access, with early-stage longevity science primarily benefiting affluent individuals while the majority are excluded on cost grounds. Whether mainstream healthcare systems will absorb these advances, or whether they remain the preserve of the wealthy, is a question the field has yet to adequately answer.
Separating Optimism from Evidence
The honest assessment of longevity biotech in 2026 is one of genuine scientific progress tempered by important caveats. The field has moved meaningfully from fringe speculation to mainstream pharmaceutical interest. Big pharma’s engagement, driven partly by the metabolic insights unlocked by the GLP-1 era, is real. Several reprogramming companies are approaching first-in-human studies. Senolytic, mitochondrial, and AI-driven drug discovery pipelines are all progressing.
At the same time, as one expert noted in a roundup published by the Lifespan.io organisation, longevity biotech has many compelling preclinical mechanisms but a comparatively thin set of rigorous human trials and hard endpoints. Despite growing excitement, no therapeutic intervention currently available has been shown to significantly outperform calorie restriction when it comes to extending lifespan in controlled human studies. That is a sobering baseline.
The field also faces the temptation of overpromising. Biohacking communities, unregulated clinics, and consumer supplement brands often borrow the language of longevity science without the accompanying evidence, and a 2025 incident in which two women were hospitalised in critical condition after receiving peptide injections at a Las Vegas longevity conference served as a reminder that this conflation carries real risks.
For now, the most credible and evidence-backed steps towards a longer healthspan remain the least glamorous: regular physical activity, a nutrient-dense diet, adequate sleep, and management of cardiovascular risk factors. The biotechnology being developed today may one day supplement or amplify those fundamentals in meaningful ways. Whether it will do so safely, equitably, and within the next decade is a question that only rigorous clinical science can answer.
